摘要
大黄始载于《神农本草经》,药理活性广泛。自身免疫性疾病是一类因机体免疫耐受功能受损而致免疫细胞及其成分对自身组织结构和功能破坏的疾病,包括动脉粥样硬化、多发性硬化、痛风、类风湿性关节炎、自身免疫性甲状腺炎、溃疡性结肠炎、1型糖尿病、IgA肾病等。近年临床和实验研究显示,大黄及其蒽醌类成分对自身免疫性疾病具有良好的治疗潜力和开发前景。该文以中医药理论为指导,综述了大黄及其主要活性成分蒽醌对自身免疫性疾病的治疗和干预作用并对其作用机制进行解析,还针对大黄及其蒽醌目前研究存在的问题提出见解,旨在为大黄及其蒽醌在自身免疫性疾病的临床治疗和科学研究方面提供参考。
Rhei Radix et Rhizoma was first recorded in Shennong Ben Cao Jing,with a wide range of pharmacological activities.Autoimmune disease is a kind of disease that damages the tissue structure and function of immune cells and their components due to the impairment of immune tolerance function,including atherosclerosis,multiple sclerosis,gout,rheumatoid arthritis,autoimmune thyroiditis,ulcerative colitis,type 1 diabetes and IgA nephropathy.In recent years,clinical and experimental studies show that Rhei Radix et Rhizoma has potential therapeutic effects on autoimmune diseases.Under the guidance of the theory of traditional Chinese medicine,this paper reviews therapeutic and intervening effects of Rhei Radix et Rhizoma and its main active ingredient anthraquinone on autoimmune diseases.It also puts forward new study directions in view of the existing problems in studies of rhubarb and its anthraquinone,with the aim to provide reference for clinical treatment and scientific studies of effect of Rhei Radix et Rhizomaon autoimmune diseases.
作者
陈其艳
傅超美
罗锐锋
林美斯
廖婉
高飞
CHEN Qi-yan;FU Chao-mei;LUO Rui-feng;LIN Mei-si;LIAO Wan;GAO Fei(School of Pharmacy,Chengdu University of Traditional Chinese Medicine,State Key Laboratory of Traditional Chinese Medicine Resources in Southwestern China,Chengdu 611137,China;Sichuan Provincial Acupuncture School,Chengdu 611731,China)
出处
《中国中药杂志》
CAS
CSCD
北大核心
2021年第1期15-23,共9页
China Journal of Chinese Materia Medica
基金
国家自然科学基金项目(81903811)
中国博士后基金面上项目(2019M653364)
成都市科技局技术创新研发项目(YF05-00267-SN)。
关键词
大黄
蒽醌
大黄酸
大黄素
自身免疫性疾病
作用机制
Rhei Radix et Rhizoma
anthraquinones
rhein
emodin
autoimmune diseases
mechanism
